The first-line drug choice for a previously healthy adult patient diagnosed with community-acquired pneumonia and an allergy to macrolides would be:

Rationale: A. While levofloxacin is effective, current antimicrobial stewardship guidelines reserve fluoroquinolones for patients with significant comorbidities or recent antibiotic use. For a previously healthy adult, using a broad-spectrum quinolone as the first choice is considered "overkill" and contributes to the development of bacterial resistance. It also carries a higher risk of serious adverse effects compared to the narrow-spectrum options appropriate for this population. B. Clarithromycin belongs to the macrolide class and is strictly contraindicated in a patient with a known macrolide allergy. Administration would likely trigger a hypersensitivity reaction, which could range from a mild cutaneous eruption to life-threatening anaphylaxis. Clinicians must always verify drug classes when an allergy is reported to avoid prescribing chemically related medications that share the same antigenic triggers. C. High-dose amoxicillin is now recommended as the primary first-line treatment for community-acquired pneumonia in healthy outpatients without risk factors. It provides excellent coverage against the most common pathogen, Streptococcus pneumoniae, which is the leading cause of bacterial pneumonia. In patients who cannot take macrolides due to allergy, amoxicillin monotherapy is a safe, effective, and narrow-spectrum alternative that aligns with stewardship goals. D. Cefpodoxime is a third-generation cephalosporin that is typically used as part of a combination regimen or for patients with specific risk factors. While it is an effective antibiotic, it is not the preferred monotherapy for a healthy adult when amoxicillin is an option. Amoxicillin remains the superior choice for its targeted efficacy against pneumococcus and its long-standing safety profile in the outpatient setting.